Drug Type CAR-T |
Synonyms CT RD06 |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Gene transference(Gene transference), T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Hodgkin Lymphoma | Phase 1 | China | 15 Apr 2020 | |
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | China | 05 Feb 2020 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | China | 05 Feb 2020 | |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | China | 05 Feb 2020 |





